Strata Critical Medical, Inc. reported $256M of revenue over the trailing twelve months, +67% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $256M (to Q2 2026). Net income: $40M, trailing twelve months to Q2 2026. Free cash flow: −$48M, trailing twelve months to Q2 2026. Operating margin: −8.2%, trailing twelve months to Q2 2026.

SRTAStrata Critical Medical, Inc.

Healthcare

$4.46-13% 1Y

$4.46

$4.0352 weeks$6.47

SRTA as reported

Strata Critical Medical, Inc. reported $256M of revenue over the trailing twelve months, +67% on the year before. 10 reported series are charted on this page, each one as filed.

$256M

Revenue, trailing twelve months · to Q2 2026 · +67% against the twelve months before

Net income: $40M
Net income · −312% year on year · trailing twelve months to Q2 2026
Free cash flow: −$48M
Free cash flow · +178% year on year · trailing twelve months to Q2 2026
Operating margin: −8.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SRTA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$256M	+67%	Q2 2026
Net income	$40M	−312%	Q2 2026
EPS	$0.49	−304%	Q2 2026
Gross margin	21%	n/a	Q2 2026
Operating margin	−8.2%	n/a	Q2 2026
Net margin	23%	n/a	Q2 2026
ROE	15%	n/a	Q2 2026
ROA	13%	n/a	Q2 2026
Free cash flow	−$48M	+178%	Q2 2026
P/E	9.10	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.